ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Immunoglobulin G2a, anti-(human antigen 17-1A) (mouse monoclonal Ho-3/TP-A-01/TPBs01 heavy chain), bidisulfide with mouse monoclonal Ho-3/TP-A-01/TPBs01 light chain, disulfide (WHO )
- Catumaxomabum (Latin)
- Catumaxomab (German)
- Catumaxomab (French)
- Catumaxomab (Spanish)
- Triomab-1 (IS)
Fresenius, Belgium; Fresenius, Israel; Fresenius Biotech, Austria; Fresenius Biotech, Denmark; Fresenius Biotech, Spain; Fresenius Biotech, France; Fresenius Biotech, Romania; Fresenius Kabi, Lithuania; Fresenius Kabi, Netherlands; Fresenius Kabi, Norway; Fresenius Medical Care, Portugal; Interlabo, Italy; Neovii Biotech, Germany; Neovii Biotech, Poland; Neovii Biotech, Slovenia; SOBI, Sweden; Swedish Orphan Biovitrum, Finland
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.